Key Points AbbVie presented new real-world VRAYLAR® results at Psych Congress 2026. Adults with major depressive disorder and bipolar I depression showed improvements in depression…
September 17, 2026
Aquestive Resubmits Anaphylm New Drug Application Following New FDA-Requested Studies
Key Points Aquestive Therapeutics has resubmitted its New Drug Application for Anaphylm™, a needle-free epinephrine treatment candidate for severe allergic reactions, including anaphylaxis. The resubmission…
September 15, 2026
Enveric Secures New U.S. Patent Allowance for Non-Hallucinogenic PTSD Drug Candidates
Key Points Enveric Biosciences received a Notice of Allowance from the U.S. Patent and Trademark Office for compounds in its EVM401 drug-candidate series. The allowance…
September 11, 2026
Cardiol Therapeutics Files US$150 Million Shelf Prospectus Ahead of CardiolRx Milestones
Key Points Cardiol Therapeutics filed a preliminary US$150 million base shelf prospectus in Canada and a related Form F-10 registration statement with the U.S. Securities…
September 09, 2026
PRISM Mid-Day Movers: Pharmaceuticals and Biotech are Today’s Leaders.
Opus Genetics, Inc. (NASDAQ: IRD) surged, up 26.5% to $5.49 today, rebounding sharply from yesterday’s $4.34 close. The stock opened at $5.33 and climbed as…
Key Points The FDA granted Breakthrough Therapy designation to Definium Therapeutics’ DT120 orally disintegrating tablet for major depressive disorder. The designation follows positive Phase 3…
September 01, 2026
MIRA-55 Moves Closer to IND as MIRA Completes Key Toxicology Studies
Key Points MIRA Pharmaceuticals completed seven-day dose-range finding toxicology and toxicokinetic studies of its oral, non-opioid inflammatory-pain candidate, MIRA-55, in rats and dogs. The studies…
Key Points ACADIA reported Q2 2026 revenue of approximately $308 million and net income of $31.5 million. Management increased 2026 revenue guidance to $1.24 billion–$1.30…
August 28, 2026
Quoin Reports Statistically Significant Interim Netherton Data, Announces Up to $50 Million Financing
Four of six patients met the primary endpoint at Week 12, while results showed improvement across multiple clinical measures. A concurrent institutional financing could extend…
Aethlon Medical (AEMD) is up 23.96% today to 2.69 from Thursday’s 2.17 close, although it has retreated from an intraday high of 3.29 after opening…
Amylyx Pharmaceuticals (NASDAQ: AMLX) is rallying sharply today, up 49.42% to 32.02 from Monday’s 21.43 close after opening at 29.93. Shares have traded from 28.00…
August 18, 2026
Amylyx Surges 33% as Avexitide Hits Primary and All Secondary Endpoints in Phase 3 LUCIDITY Trial
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a clinical-stage pharmaceutical company, announced positive topline results on August 18, 2026 from the Phase 3 LUCIDITY trial of avexitide…